Phase I/IIa Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2
Latest Information Update: 17 Mar 2025
At a glance
- Drugs RAAVrh74.MCK.GALGT2 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- 13 Mar 2025 Status changed from active, no longer recruiting to completed.
- 26 Jul 2022 Planned End Date changed from 1 Jun 2022 to 1 Oct 2023.
- 21 Apr 2022 Planned End Date changed from 1 Nov 2021 to 1 Jun 2022.